CIA
TCRT icon

Capital Impact Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Capital Impact Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10
Closed -$13K – 277
2015
Q3 		$13K Hold
10
– – 0.01% 259
2015
Q2 		$18K Buy
+10
New +$15.5K 0.01% 263

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Impact Advisors's TCRT Position: Q4 2015 in Review

Capital Impact Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2015, closing a stake of 10 shares — an estimated $13K sold.

Capital Impact Advisors first reported a position in TCRT in Q2 2015 and held it in 2 quarters. The position peaked at $18K in Q2 2015. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2015.

  • Capital Impact Advisors reported no remaining Alaunos Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 10 Alaunos Therapeutics shares in Q4 2015, an estimated $13K.
  • Capital Impact Advisors first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 2 quarters.
  • Capital Impact Advisors's Alaunos Therapeutics position peaked at $18K in Q2 2015.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2015.

Based on Capital Impact Advisors's 13F filing for Q4 2015, filed 11 Jan 2016.